213598-11-9

Usage

Uses

Used in Pharmaceutical Industry:
METHYL 3-CYANO-4-ISOPROPOXYBENZOATE is used as a building block in the synthesis of various pharmaceutical drugs, particularly those used to treat pain and inflammation. Its chemical properties make it a valuable component in the development of effective medications.
Used in Agricultural Industry:
METHYL 3-CYANO-4-ISOPROPOXYBENZOATE is used as an active ingredient in the production of insecticides and fungicides due to its pesticidal properties. It helps protect crops from pests and diseases, ensuring a healthy and productive agricultural yield.
Proper handling and storage of METHYL 3-CYANO-4-ISOPROPOXYBENZOATE are necessary to ensure safety and prevent harm to human health and the environment.

Upstream product

• 213598-10-8 methyl 3-bromo-4-isopropoxybenzoate 
• 557-21-1 dicyanozinc 
• 190271-78-4 methyl 3-formyl-4-isopropoxy-benzoate 
• 35826-59-6 methyl 4-isopropoxybenzoate 
• 24589-99-9 methyl 3-formyl-4-hydroxybenzoate 
• 75-30-9 2-iodo-propane 
• 773837-37-9 sodium cyanide 
• 15126-06-4 methyl 3-iodo-4-hydroxybenzoate 
• 29415-97-2 methyl 3-bromo-4-hydroxybenzoate 
• 14348-41-5 3-bromo-4-hydroxy-benzoic acid 
• 99-76-3 methyl 4-hydroxylbenzoate 
• 557-21-1 zinc(II) cyanide 
• 258273-31-3 3-cyano-4-isopropoxybenzoic acid 
• 67-56-1 methanol 

Downstream Products

• 258273-31-3 3-cyano-4-isopropoxybenzoic acid 
• 1072947-68-2 5-[3-(1H-indazol-5-yl)-1,2,4-oxadiazol-5-yl]-2-[(1-methylethyl)oxy]benzonitrile 
• 1312009-22-5 ethyl 4-[6-chloro-5-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1H-indazol-1-yl]butanoate 
• 1312009-23-6 ethyl 4-[5-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-6-methyl-1H-indazol-1-yl]butanoate 
• 1312009-61-2 ethyl 4-[5-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-6-ethyl-1H-indazol-1-yl]butanoate 
• 1312009-26-9 ethyl 4-[5-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-6-(methyloxy)-1H-indazol-1-yl]butanoate 
• 1312009-30-5 5-[3-(1H-indazol-4-yl)-1,2,4-oxadiazol-5-yl]-2-[(1-methylethyl)oxy]benzonitrile 
• 1312009-57-6 4-[6-chloro-5-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1H-indazol-1-yl]butanoic acid 
• 1312009-58-7 4-[5-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-6-methyl-1H-indazol-1-yl]butanoic acid 
• 1312009-60-1 4-[5-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-6-ethyl-1H-indazol-1-yl]butanoic acid 
• 1312035-13-4 4-[5-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-6-(methyloxy)-1H-indazol-1-yl]butanoic acid 
• 1167416-06-9 1,1-dimethylethyl 6-(5-{3-cyano-4-[(1-methylethyl)oxy] phenyl}-1,2,4-oxadiazol-3-yl)-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate 
• 1306760-86-0 5-(3-{(1S)-1-[(2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-4-yl}-1,2,4-oxadiazol-5-yl)-2-[(propan-2-yl)oxy]benzonitrile 
• 1307812-65-2 5-(7-bromo-4,5-dihydronaphtho[1,2-c]isoxazol-3-yl)-2-isopropoxybenzonitrile 

Relevant academic research and scientific papers

AMINO ALCOHOL DERIVATIVE, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF

The present invention belongs to the field of medicine, and specifically discloses an amino alcohol derivative represented by Formula I, a pharmaceutically acceptable salt, solvate, polymorph or prodrug thereof. In addition, the present invention also discloses a pharmaceutical composition comprising the above substances, and a use of the substance in the preparation of a medicament for the prevention and treatment of an immune inflammatory disease, or a disease or condition associated with immunological competence such as multiple sclerosis, ALS, CIDP, systemic lupus erythematosus, rheumatoid arthritis, ulcerative colitis, psoriasis, polymyositis, etc.

3-cyano-4-alcoholate benzoate synthesis method

The invention discloses a 3-cyano-4-alcoholate benzoate synthesis method. The general formula for the reaction is shown in the description, wherein R1 is isopropyl or other alkyls, and R2 is alkyl. The reaction condition of the method is mild, the raw materials are easy to get, the yield is high, the post-processing is simple, and the method provides an important reference for the industrial production.

OXADIAZOLE MODULATORS OF S1P METHODS OF MAKING AND USING

The invention is directed to Compounds of Formula (I): wherein each variable is defined herein, as well as methods of making and using the compounds as agonists of S1P1 and/or S1P5 for instance for treating graft versus host disease and autoimmune diseases.

Preparation method of 3-cyano-4-isopropoxy methyl benzoate

The invention discloses a preparation method of 3-cyano-4-isopropoxy methyl benzoate. The preparation method comprises the following steps: step I, preparing 3-aldehyde-4-methyl hydroxybenzoate from methyl p-hydroxybenzoate; step II, preparing 3-cyano-4-m

Method for preparing 3-cyano-4-isopropoxybenzoic acid

The invention discloses a method for preparing 3-cyano-4-isopropoxybenzoic acid. A first step, 3-formyl-4-methyl hydroxybenzoate is prepared with methyl parahydroxybenzoate; a second step, 3-cyano-4-methyl hydroxybenzoate is prepared with the 3-formyl-4-methyl hydroxybenzoate; a third step, 3-cyano-4-methyl isopropoxybenzoate is prepared with the 3-cyano-4-methyl hydroxybenzoate; a fourth step, the 3-cyano-4-isopropoxybenzoic acid is prepared with the 3-cyano-4-methyl isopropoxybenzoate. The preparation method of the 3-cyano-4-isopropoxybenzoic acid, which is provided by the invention, has the advantages that 1) the use of the cuprous cyanide of hypertoxic cyanide in a previous process is avoided, and the method is more suitable for industrialization; 2) cyano is prepared by formyl, and the method is high-efficiency and direct, and is suitable for quantity production; 3) all raw materials are cheap and easily obtained, and the cost advantage is obvious.

DEUTERIUM-SUBSTITUTED OXADIAZOLES

Described are deuterated modulators of S1P1 receptors, pharmaceutical compositions thereof, and methods of use thereof.

OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS

Oxadiazole substituted indazole derivatives of formula (I) or pharmaceutical salts thereof having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their uses in the treatment of various disorders mediated by S1P1 receptors are disclosed.

OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS

Oxadiazole substituted indazole derivatives of formula (I) or pharmaceutical salts thereof having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their uses in the treatment of various disorders mediated by S1P1 receptor are disclosed.

TRICYCLIC HETEROCYCLIC COMPOUNDS

Disclosed are compounds of Formula (I) or stereoisomers or salts thereof, wherein: X1, X2, X3, W, Q1, Q2, and G2 are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Modulators of S1P and Methods of Making And Using

The invention is directed to Compounds of Formula I: as well as methods of making and using the compounds.